2012
Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
De Souza A, Strober B, Merola J, Oliver S, Franks A. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. Journal Of Drugs In Dermatology 2012, 11: 1224-6. PMID: 23134988.Peer-Reviewed Original ResearchConceptsDiscoid lupus erythematosusDiscoid lupusLupus erythematosusCutaneous Lupus Erythematosus Disease AreaFirst open-label studyTh17-mediated immune responsesOpen-label studyChronic inflammatory disordersEffective therapeutic optionDays of treatmentAdverse eventsIL-23Psoriatic arthritisIL-12Clinical efficacyTherapeutic optionsInflammatory disordersTh1 cellsTreatment modalitiesLeukocyte productionImmune responseLabel studyEnzyme inhibitorsApremilastPilot study
2008
Balancing Immunity and Immunosuppression: Vaccinating Patients Receiving Treatment with Efalizumab
Marmon S, Strober B. Balancing Immunity and Immunosuppression: Vaccinating Patients Receiving Treatment with Efalizumab. Journal Of Investigative Dermatology 2008, 128: 2567-2569. PMID: 18927537, DOI: 10.1038/jid.2008.291.Peer-Reviewed Original Research